Hims & Hers Health, Inc. 8-K

What Happened

• Hims & Hers Health, Inc. filed an 8-K dated July 1, 2026, disclosing that two of its subsidiaries, XeCare LLC and Apostrophe Pharmacy LLC (the “Sellers”), entered into a Master Receivables Purchase Agreement (RPA) with JPMorgan Chase Bank, N.A. as purchaser on July 1, 2026. The RPA creates a receivables purchase facility with a $400,000,000 facility limit.
• The Company also entered Amendment No. 4 to its Revolving Credit and Guaranty Agreement (dated June 26, 2026) to permit the RPA and add a new permitted-indebtedness basket allowing up to $400,000,000 of indebtedness related to the RPA.

Key Details

• Facility limit: $400,000,000 under the Master Receivables Purchase Agreement (dated July 1, 2026).
• Term: RPA initial term is 364 days and may be extended in one‑year increments by written agreement.
• Company guarantee: Hims & Hers provided a Performance Undertaking guaranteeing the Sellers’ performance under the RPA, but it explicitly does not guarantee collectability of receivables or the Sellers’ creditworthiness.
• Credit agreement amendment (dated June 26, 2026) added a permitted indebtedness basket and updated lien/collateral provisions; otherwise loans, interest, fees, covenants and defaults remain unchanged.

Why It Matters

• This transaction gives Hims & Hers a new source of near-term cash tied to selling eligible receivables (up to $400M), which can help with working capital and liquidity management.
• The company’s guarantee covers the Sellers’ contractual performance under the RPA but does not shift credit risk on the underlying receivables to Hims & Hers, and JPMorgan may decline purchases at its discretion.
• The credit agreement amendment preserves the company’s existing loan economics and covenants while formally allowing the receivables facility, reducing legal/contractual friction for accessing this financing option.